Abstract
Newborn sepsis is a major cause of child mortality across the world. Strategies for prevention and treatment have the potential to save many newborns from a sepsis-related death. Among the various parenteral antibiotic options possible, there is considerable experience with the use of penicillins, cephalosporins, and aminoglycosides. Ciprofloxacin is also increasingly accepted as safe in the neonate. However, the available evidence is not of high quality, and adequate research is required to specifically address dosage schedules, safety, and efficacy of ciprofloxacin to lead to established interventions to reduce morbidity and mortality for neonatal sepsis.

This publication has 17 references indexed in Scilit: